There is a wonderfully inconvenient moment in a long executive career when experience can become either a compass or a cushion. Maulik Nanavaty had earned a very comfortable cushion. He had spent sixteen years at Baxter, then eighteen more at Boston Scientific. He had run a country operation in Japan, crossed from strategy into general management, and led a global neuromodulation business worth more than $1 billion. The machinery around him was large, tested and polished. Then, in 2023, he left it for Anumana, a young company attempting to turn artificial intelligence into a medical product that clinicians might trust and actually use.
The interesting part is not that an established executive joined an AI company. By now, that migration is its own corporate weather pattern. The interesting part is his explanation. He could have continued toward a conventional public-company chief executive role. Instead, he said he would regret missing a consequential technology shift from the sideline. So he chose the uncertain seat, close to the work.
This was no moonshot tourist arriving with a suitcase full of futurist nouns. Nanavaty brought the habits of a medical-device operator: evidence before exuberance, workflow before wonder, and a rather bracing affection for discussing risk. His version of AI has forms to file, systems to integrate, payment pathways to establish and busy users who possess no spare patience for a charming demonstration.
The useful education of not knowing
Nanavaty earned a doctorate in pharmaceutical sciences at the University of Illinois. He joined Baxter in his early career, by his own account, without a precise map of what he would do. That uncertainty became an education. He worked across regulatory and clinical functions, business development and acquisitions, then went back to school for an M.B.A. at the University of Chicago. A laboratory-trained mind was learning the varied dialects spoken between an invention and a business.
Japan supplied the next lessons. At Baxter and later Boston Scientific, he moved into operating roles where strategy could no longer live as an elegant slide. He led the interventional cardiology business in Japan, then served as president and representative director of Boston Scientific Japan from late 2007 to 2011. Country leadership is where abstraction meets the invoice, the regulator, the customer and the Monday morning meeting. It punishes theory with admirable efficiency.
Back in the United States, he took charge of Boston Scientific’s Neuromodulation division in September 2011. The job placed research, product development, commercialization and operations within the same field of vision. Over roughly twelve years, the unit grew past $1 billion. It also forced a scientist and international commercial operator to become fluent in another form of translation: how a sophisticated device becomes a reliable part of ordinary practice.
The magic trick is to disappear
Anumana gave him a different material to work with. Co-founded by nference and Mayo Clinic, the company builds software that finds patterns in standard electrocardiogram data and is developing tools for use around cardiac procedures. Its scientific premise is ambitious. Nanavaty’s commercial premise is almost comic in its plainness: do not make the user work harder.
“The technology has to remain invisible,” he has said. This is not a request for timid design. It is a demand that complexity stay backstage. A clinician facing a short appointment and a consequential decision is unlikely to welcome five extra clicks, a new ritual or a side expedition through somebody else’s clever interface. Information has value at the point where it changes a decision. Arrive late, arrive awkwardly, or arrive with homework, and even a powerful system can become an expensive ornament.
The philosophy has a revealing humility. Technology companies often want the product to be admired. Nanavaty wants it to be absorbed. The better it fits, the less ceremony it requires. In this view, the final mile of AI is not a triumphant model score. It is the mundane choreography of an existing day: the test already ordered, the result delivered in time, the answer presented clearly, the professional still in command.
That insistence also explains why he talks so much about validation, regulatory trust and reimbursement. They can sound like dull supporting characters in the opera of innovation. In practice, they decide whether the opera opens. Anumana’s work has relied on large longitudinal datasets, clinical studies and regulatory review. Its lead ECG-AI product became eligible for Medicare reimbursement in January 2025. Each milestone removes a different objection: Does it work? Is it appropriate to use? Can a health system afford to make it routine?
Put the risk on the table
Nanavaty’s candor becomes most vivid when he discusses fundraising. His suggested pitch begins with the hazards: here is the risk, here is how the company intends to reduce it, and here is the opportunity that remains. Most founders are trained to enter a room carrying sunshine. He recommends bringing a weather map.
The approach is not gloomy. It is a way to create trust before asking for belief. Medical technology contains obvious uncertainties in research, regulation, adoption and financing. Pretending otherwise merely transfers the anxiety to the listener. Naming the risks allows a team to attach actions and milestones to them. It also disciplines ambition. Nanavaty advises leaders to identify the few things that matter now, stay with them until a defined point, and resist the buffet of impressive possibilities.
That discipline acquired an elegant twist in April 2025. Boston Scientific, his employer of eighteen years, joined Anumana’s Series C financing. The investment supported an expansion from diagnostic algorithms toward generative imaging and real-time tools around procedures, including planned collaboration in electrophysiology. A former employer becoming an investor is not a sentimental reunion. It is a serious vote that the old operating world sees value in the new one.
There are now three titles on Nanavaty’s current biography: chief executive of Anumana, president of Ventures at nference, and chief executive of Vimana. The constellation suggests that his job is larger than supervising one product. He sits at the junction where research, venture building and commercialization must agree on what can travel from a dataset into daily use.
An old instrument, a new argument
There is a pleasing tension at the center of the Anumana story. The company’s work begins with an instrument whose history stretches back more than a century. The newness lives in interpretation. Nanavaty likes this gap: familiar input, deeper reading. It gives innovation a foothold in behavior that already exists.
By March 2026, Anumana said the evidence behind its platform had grown to more than 100 peer-reviewed publications, with 19 added in the previous year. It also reported more than 300 patents, 116 of them granted. That same month, the company appeared on Fast Company’s Most Innovative Companies list in the medical-devices category. Nanavaty’s response credited the team and returned to the practical work of validated tools in everyday care. Even the victory lap came with sensible shoes.
His résumé spans science, corporate strategy, Japan, global operations, implantable hardware and AI software. The connecting thread is translation. Each move asked him to carry an idea across a border: from research into a product, from one market into another, from a technical capability into a commercial system. Translation is unglamorous only to people who have never watched a fine idea die of poor instructions.
The choice he made in 2023 now looks less like a departure from his career than its logical test. Thirty-four years inside established companies taught him how institutions accept something new. Anumana asks whether that knowledge can help a young company avoid confusing invention with arrival. There is no guarantee, which was precisely the attraction. He wanted to be in the thick of it.
The wager is simple enough to fit on a card. Powerful technology should not demand applause from the people using it. It should earn trust, enter quietly and improve the next decision. For an executive who left scale to chase uncertainty, Nanavaty has arrived at a philosophy of remarkable restraint. The future, if he gets his way, will be sophisticated underneath and almost ordinary on top.